/programmes---services/programmes-and-services.png?sfvrsn=cbf1476f_1)
HORG plays a pivotal role in advancing cancer research and treatment through their comprehensive services for clinical trials, by combining multidisciplinary teams and expertise with state-of-the-art knowledge and technologies. Here are some key services provided:
/programmes---services/1.png?sfvrsn=4cb9879c_1)
The team is able to design and conduct innovative clinical trials.
We have a team of well-trained and senior clinicians who are actively engaged in identifying and enrolling patients into clinical trials.
NCIS has tumour-specific multidisciplinary teams comprising surgeons, oncologists, radiologists, pathologists, nurses, and study coordinators who work closely together to ensure comprehensive patient care and thorough trial execution.
Patients enrolled in our clinical trials have access to advanced medical equipment and facilities for tumour molecular profiling as well as treatment efficacy and safety assessments.
Our team works closely with Institutional Review Boards (IRBs) to ensure patient safety and research integrity.
Patients enrolled in clinical trials at HORG will receive personalised care, support, and resources to manage potential side effects.
Our biostatisticians and data analysts will ensure accurate interpretation of trial results and provide statistical insights.
We offer training opportunities for doctors and study coordinators with a full range of clinical trial activities, including trial procedures, safety protocols, and ethical considerations.
Our clinical trial coordinators manage various aspects of clinical trials and ensure adherence to protocol guidelines.
Our clinical trial unit has extensive collaborations and networking with academic and industry research partners within and outside of Singapore, offering our patients a wide range of clinical trial opportunities.
After trial completion, we contribute to the research findings through publications in scientific journals and/or conference presentations to the broader scientific community.
/programmes---services/2.png?sfvrsn=c4ce20e9_1)
In the Phase I clinic, a team of senior oncologists from NCIS reviews new patients for suitability to be enrolled into early phase clinical trials, as well as follow-up patients who have been enrolled into early phase clinical trials to ensure safety and review treatment efficacy from novel therapies. An early phase clinical trial programme offers cutting-edge treatments to patients who have exhausted standard therapies or for whom no effective treatments exist.
The goal of Precision Oncology is to tailor medical care in accordance with the unique genetic and molecular characteristics of an individual's cancer. It involves using advanced technologies, such as genomic sequencing and molecular profiling, to identify specific genetic mutations and alterations in a patient's tumour; the patient is then matched to the most appropriate cancer therapy based on the specific characteristics of his/her tumour, instead of the conventional one-size-fits-all approach. This personalised and targeted strategy can lead to improved outcomes and better quality of life for patients.
/programmes---services/3.png?sfvrsn=63b3b4d4_1)
/programmes---services/tissue-and-blood-banking.png?sfvrsn=b259dc97_1)
Systematic and prospective storage of tissue and blood samples from cancer patients into biobanks plays a crucial role in advancing cancer research and personalised treatment for cancer patients. The study of these samples can contribute to the characterisation of the molecular and genetic features of tumours, understanding the mechanisms of cancer development and treatment resistance, identification of biomarkers that can be used to select patients for different treatments, as well as the development of new cancer therapies.
